<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524963</url>
  </required_header>
  <id_info>
    <org_study_id>021-402-00016</org_study_id>
    <nct_id>NCT03524963</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea</brief_title>
  <official_title>A Randomized, Open Label, Multiple Does, Crossover Study to Compare the Safety/Tolerability and Pharmacokinetics Between Pleetal SR Cap. and Cilostan CR Tab. in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bundang CHA Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multiple-dose, two-sequence, two-period crossover study to
      to compare the safety/tolerability and pharmacokinetics between Pletaal SR Cap. and Cilostan
      CR Tab. in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility for participation of this study will be determined from demographic information,
      medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests
      within 4 weeks before study drug administration. Subjects suitable for this study will be
      admitted to the Clinical Trial Center of CHA Bundang Medical Center on the day before dosing
      (Day -1).

      From Day 1 to 5, Subjects will be dosed study drug (Pletaal SR Cap. 200 mg once a day or
      Cilostan CR Tab. 200mg once a day).

      Pharmacokinetic samplings will be done upto 24 hours after 1st study drug dosing and upto 72
      hours after 5th study drug dosing.

      After 9 days of washout period (Day 15), Subjects will be dosed study drug and
      pharmacokinetic samplings will be done by crossover manner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 24 hours after 1st dose</time_frame>
    <description>Maximal plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>up to 24 hours after 1st dose</time_frame>
    <description>Area under the time-concentration curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>up to 72 hours after 5th dose</time_frame>
    <description>Maximal plasma concentration at steady-state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>up to 24 hours after 5th dose</time_frame>
    <description>Area under the time-concentration curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Up to 30 days after final dose</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostan CR Tab.</intervention_name>
    <description>Cilostan CR Tab. 200mg once a day for 5 days</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pletaal SR Cap.</intervention_name>
    <description>Pletaal SR Cap. 200mg once a day for 5 days</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 20 - 45 years

          -  BMI (body mass index) between 18.0 and 27.0

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic,
             gastrointestinal disease or mental disorder (Past history or present)

          -  Inadequate result of laboratory test (especially, ALT/AST/r-GTP/ALP/LDH/Total
             bilirubin &gt; 1.5 x UNL)

          -  Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab

          -  Taking OTC (Over the counter) medicine including oriental medicine within 7 days

          -  Clinically significant allergic disease

          -  Subject with known for hypersensitivity reaction to Cilostazol

          -  Previous whole blood donation within 60 days or component blood donation within 30
             days

          -  Previous participation of other trial within 90 days

          -  Continued taking caffeine (caffeine &gt; 5 cup/day), drinking (alcohol &gt; 30 g/day) and
             severe heavy smoker (cigarette &gt; 1/2 pack per day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Doo-Yeoun Cho, MD, PhD</last_name>
    <phone>+82-31-780-5030</phone>
    <email>dooycho@cha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo-Yeoun Cho, MD, PhD</last_name>
      <phone>+82-31-780-5030</phone>
      <email>dooycho@cha.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 13, 2018</last_update_submitted>
  <last_update_submitted_qc>May 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bundang CHA Hospital</investigator_affiliation>
    <investigator_full_name>MinYoung Kim, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

